Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide

Tamsin R. Sheen, Courtney K. Cavaco, Celia M. Ebrahimi, Marilyn L. Thoman, Sam Sanderson, Edward L. Morgan, Kelly S. Doran

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is a serious health concern worldwide that requires new therapeutic approaches that extend beyond the development and use of new antibiotics. In this study, a conformationally biased, response-selective agonist of human C5a, known as EP67, was used to induce host innate immunity as a therapeutic method of reducing CA-MRSA infections. Using a murine model of dermonecrosis we show that EP67 treatment effectively limits CA-MRSA infection by promoting cytokine synthesis and neutrophil influx. In contrast, EP67 was ineffective in reducing lesion formation in C5a receptor (CD88-/-) knockout mice, indicating that EP67 activates host innate immunity by engagement of CD88 bearing cells. These results suggest that EP67 may serve as a novel immunotherapeutic for prevention and treatment of CA-MRSA dermal infection.

Original languageEnglish (US)
Pages (from-to)9-13
Number of pages5
JournalVaccine
Volume30
Issue number1
DOIs
StatePublished - Dec 9 2011

Fingerprint

Methicillin-Resistant Staphylococcus aureus
peptides
Peptides
Infection
Innate Immunity
infection
Anaphylatoxin C5a Receptor
therapeutics
Knockout Mice
lesions (animal)
agonists
neutrophils
Neutrophils
cytokines
animal models
antibiotics
Cytokines
Anti-Bacterial Agents
Skin
receptors

Keywords

  • C5a agonist
  • CA-MRSA
  • EP67
  • Innate immunity
  • PMN
  • Staphylococcus aureus

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Sheen, T. R., Cavaco, C. K., Ebrahimi, C. M., Thoman, M. L., Sanderson, S., Morgan, E. L., & Doran, K. S. (2011). Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide. Vaccine, 30(1), 9-13. https://doi.org/10.1016/j.vaccine.2011.10.054

Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide. / Sheen, Tamsin R.; Cavaco, Courtney K.; Ebrahimi, Celia M.; Thoman, Marilyn L.; Sanderson, Sam; Morgan, Edward L.; Doran, Kelly S.

In: Vaccine, Vol. 30, No. 1, 09.12.2011, p. 9-13.

Research output: Contribution to journalArticle

Sheen, TR, Cavaco, CK, Ebrahimi, CM, Thoman, ML, Sanderson, S, Morgan, EL & Doran, KS 2011, 'Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide', Vaccine, vol. 30, no. 1, pp. 9-13. https://doi.org/10.1016/j.vaccine.2011.10.054
Sheen, Tamsin R. ; Cavaco, Courtney K. ; Ebrahimi, Celia M. ; Thoman, Marilyn L. ; Sanderson, Sam ; Morgan, Edward L. ; Doran, Kelly S. / Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide. In: Vaccine. 2011 ; Vol. 30, No. 1. pp. 9-13.
@article{97d21621c93248828498e1159d548695,
title = "Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide",
abstract = "The emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is a serious health concern worldwide that requires new therapeutic approaches that extend beyond the development and use of new antibiotics. In this study, a conformationally biased, response-selective agonist of human C5a, known as EP67, was used to induce host innate immunity as a therapeutic method of reducing CA-MRSA infections. Using a murine model of dermonecrosis we show that EP67 treatment effectively limits CA-MRSA infection by promoting cytokine synthesis and neutrophil influx. In contrast, EP67 was ineffective in reducing lesion formation in C5a receptor (CD88-/-) knockout mice, indicating that EP67 activates host innate immunity by engagement of CD88 bearing cells. These results suggest that EP67 may serve as a novel immunotherapeutic for prevention and treatment of CA-MRSA dermal infection.",
keywords = "C5a agonist, CA-MRSA, EP67, Innate immunity, PMN, Staphylococcus aureus",
author = "Sheen, {Tamsin R.} and Cavaco, {Courtney K.} and Ebrahimi, {Celia M.} and Thoman, {Marilyn L.} and Sam Sanderson and Morgan, {Edward L.} and Doran, {Kelly S.}",
year = "2011",
month = "12",
day = "9",
doi = "10.1016/j.vaccine.2011.10.054",
language = "English (US)",
volume = "30",
pages = "9--13",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide

AU - Sheen, Tamsin R.

AU - Cavaco, Courtney K.

AU - Ebrahimi, Celia M.

AU - Thoman, Marilyn L.

AU - Sanderson, Sam

AU - Morgan, Edward L.

AU - Doran, Kelly S.

PY - 2011/12/9

Y1 - 2011/12/9

N2 - The emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is a serious health concern worldwide that requires new therapeutic approaches that extend beyond the development and use of new antibiotics. In this study, a conformationally biased, response-selective agonist of human C5a, known as EP67, was used to induce host innate immunity as a therapeutic method of reducing CA-MRSA infections. Using a murine model of dermonecrosis we show that EP67 treatment effectively limits CA-MRSA infection by promoting cytokine synthesis and neutrophil influx. In contrast, EP67 was ineffective in reducing lesion formation in C5a receptor (CD88-/-) knockout mice, indicating that EP67 activates host innate immunity by engagement of CD88 bearing cells. These results suggest that EP67 may serve as a novel immunotherapeutic for prevention and treatment of CA-MRSA dermal infection.

AB - The emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is a serious health concern worldwide that requires new therapeutic approaches that extend beyond the development and use of new antibiotics. In this study, a conformationally biased, response-selective agonist of human C5a, known as EP67, was used to induce host innate immunity as a therapeutic method of reducing CA-MRSA infections. Using a murine model of dermonecrosis we show that EP67 treatment effectively limits CA-MRSA infection by promoting cytokine synthesis and neutrophil influx. In contrast, EP67 was ineffective in reducing lesion formation in C5a receptor (CD88-/-) knockout mice, indicating that EP67 activates host innate immunity by engagement of CD88 bearing cells. These results suggest that EP67 may serve as a novel immunotherapeutic for prevention and treatment of CA-MRSA dermal infection.

KW - C5a agonist

KW - CA-MRSA

KW - EP67

KW - Innate immunity

KW - PMN

KW - Staphylococcus aureus

UR - http://www.scopus.com/inward/record.url?scp=84858600671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858600671&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.10.054

DO - 10.1016/j.vaccine.2011.10.054

M3 - Article

VL - 30

SP - 9

EP - 13

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 1

ER -